<?xml version="1.0" encoding="UTF-8"?>
<p>In terms of clinical relevance, according to the pre‐defined MID, the primary analysis showed no 'clinically relevant' differences. However, adopting alternative guidance on the interpretation of the individual elements of the EORTC QLQ‐C30 questionnaire suggests that all but Pain at 3 months, which favoured CTDa in the non‐intensive pathway, was unlikely to have much clinical relevance (Cocks 
 <italic>et al</italic>, 
 <xref rid="bjh15459-bib-0006" ref-type="ref">2011</xref>). This same interpretation would have been the conclusion had we adopted alternative criteria where anything between a 6‐ and 17‐point difference in any sub‐scale is regarded as clinically relevant (Kvam 
 <italic>et al</italic>, 
 <xref rid="bjh15459-bib-0011" ref-type="ref">2010</xref>).
</p>
